Northland Securities Begins Coverage on TriSalus Life Sciences (NASDAQ:TLSI)

Northland Securities initiated coverage on shares of TriSalus Life Sciences (NASDAQ:TLSI) in a research report released on Friday, MarketBeat reports. The brokerage issued an outperform rating and a $12.50 price target on the stock.

Other research analysts have also issued research reports about the stock. Oppenheimer began coverage on shares of TriSalus Life Sciences in a research note on Monday, September 16th. They set an “outperform” rating and a $10.00 price objective for the company. Canaccord Genuity Group reaffirmed a “buy” rating and set a $12.00 price target on shares of TriSalus Life Sciences in a research report on Thursday, June 27th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, TriSalus Life Sciences currently has a consensus rating of “Buy” and an average price target of $12.50.

TriSalus Life Sciences Trading Down 1.0 %

Shares of NASDAQ TLSI opened at $4.07 on Friday. The stock has a market capitalization of $110.54 million, a PE ratio of -1.63 and a beta of 0.47. TriSalus Life Sciences has a 12-month low of $3.32 and a 12-month high of $10.42. The stock’s fifty day simple moving average is $4.70 and its two-hundred day simple moving average is $6.34.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its earnings results on Wednesday, August 14th. The company reported ($0.21) earnings per share (EPS) for the quarter. The business had revenue of $7.36 million during the quarter. On average, equities analysts predict that TriSalus Life Sciences will post -1.53 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Mary T. Szela acquired 7,520 shares of the company’s stock in a transaction dated Thursday, September 12th. The shares were purchased at an average cost of $5.20 per share, with a total value of $39,104.00. Following the completion of the acquisition, the chief executive officer now directly owns 377,382 shares of the company’s stock, valued at $1,962,386.40. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 76.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Wolverine Asset Management LLC purchased a new stake in TriSalus Life Sciences in the second quarter valued at approximately $240,000. Highbridge Capital Management LLC acquired a new stake in TriSalus Life Sciences during the 2nd quarter valued at approximately $1,184,000. Finally, Duquesne Family Office LLC lifted its stake in TriSalus Life Sciences by 35.1% during the 2nd quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock valued at $2,357,000 after acquiring an additional 110,966 shares during the period. 2.58% of the stock is owned by institutional investors and hedge funds.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.